Research programme: heavy metal poisoning therapeutics - Medesis Pharma

Drug Profile

Research programme: heavy metal poisoning therapeutics - Medesis Pharma

Alternative Names: Americium decorporation - Medesis Pharma; Curium decorporation - Medesis Pharma; NU 01; NU 02; NU 03

Latest Information Update: 12 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medesis Pharma
  • Developer CEA; Medesis Pharma
  • Class
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Heavy metal poisoning

Most Recent Events

  • 12 Aug 2016 Preclinical development is ongoing for Heavy metal poisoning (Medesis pipeline, August 2016)
  • 26 Mar 2014 Medesis Pharma and CEA enter into a collaboration for development of compounds for Heavy metal poisoning
  • 19 Feb 2014 Medesis Pharma and CEA file for patent protection for decorporation process for distribution of chelators using the Aonys®
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top